Clinical trials: Patients with Multiple Sclerosis
Erectile Dysfunction Due to Diseases Classified Elsewhere, Multiple Sclerosis, Relapsing-Remitting
Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is an inflammatory disease that affects the brain and spinal cord. There are potential impacts on neurological functions, including sensory and autonomic functions.
- Trial name
- NCT05615454
- Testing
- bio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product).
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis
Walking Fatigability,Saptiotemporal Gait Parameters and Falling in MS Patients
This observational study aims to investigate the relationship between walking fatigability, changes in spatiotemporal gait parameters, and risk of falling in individuals with multiple sclerosis (MS).
- Trial name
- WF-GAIT-FALL (NCT07524556)
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Ibrahim Ahmad Elmongy
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
The Effect of Virtual Reality on Fatigue and Functional Capacity in Patients With MS
This clinical trial aims to evaluate the effectiveness of virtual reality (VR) as a complementary intervention to traditional physical therapy for individuals diagnosed with Multiple Sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Virtual Reality
- Trial name
- VRMS (NCT06987994)
- Testing
- control group( physical therapy), Experemental group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istinye University
Relapsing Forms of Multiple Sclerosis
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
This was a non-interventional, cross-sectional, multicentric, and nationwide study, based on primary and secondary data collection.
- Trial name
- CRONOS-MS (NCT06251986)
- Testing
- ofatumumab
- Where
- 31 sites in Spain
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with…
- Trial name
- NCT07483450
- Testing
- Ocrelizumab
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
This study evaluated the efficacy and safety of Everolimus in treating patients with Subependymal Giant Cell Astrocytomas associated with Tuberous Sclerosis Complex.
- Trial name
- EXIST-1 (NCT00789828)
- Testing
- Everolimus
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, NMO Spectrum Disorder
Epidemiological Characteristics of COVID-19 in Patients With MS or NMO
The purpose of this study is to collect French medical data for patients with Multiple Sclerosis (MS) or NeuroMyelitis Optica (NMO) spectrum disorder who are diagnosed or strongly suspected of being infected with Covid19.
- Conditions
- Multiple Sclerosis, NMO Spectrum Disorder, COVID-19
- Trial name
- COVISEP (NCT04355611)
- Testing
- Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)
- Where
- France
- Volunteers
- 2,465 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Secondary Progressive Multiple Sclerosis
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia.
- Trial name
- EMBOSSES (NCT07168694)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Patient Experiences of Multiple Sclerosis (PExMS)
Besides coping with the diagnosis, people with multiple sclerosis have to make complex decisions such as deciding about immunotherapies.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Patient Engagement, Self Efficacy
- Trial name
- PExMS (NCT04236544)
- Testing
- PExMS and DECIMS-Wiki, DECIMS-Wiki
- Volunteers
- 55 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized
Universal CAR-T Cells in Patients with Refractory Autoimmune Diseases of the Nervous System.
This is an open label, single-site, dose-escalation study in up to 25 participants with refractory autoimmune diseases of nervous system.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Myasthenia Gravis, Generalized, Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- NCT06485232
- Testing
- Universal BCMA CAR-T, Universal CD19 CAR-T, Universal BCMA CAR-T; Universal CD19 CAR-T
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple Sclerosis
Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic…
- Trial name
- LEMTRADA-ITP (NCT03784898)
- Testing
- Blood draw for future biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
RRMS: Disease PROgression and Myeloid Profiling After Bone Marrow TRANSPLANTation and Second Line Therapies
To study whether highly effective therapies can halt disease progression in people with multiple sclerosis by modulating the peripheral myeloid landscape.
- Trial name
- TRANSPLANTPRO (NCT06267781)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis
Gene Expression Profiles in Multiple Sclerosis (MS)
The purpose of this study is to test differences in RNA levels between Multiple Sclerosis (MS) patients and normal subjects. RNA provides a "message" from genes altered in diseases.
- Trial name
- NCT00704834
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Multiple Sclerosis, Primary Progressive
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily can prevent worsening of walking ability in people PPMS. The number of participants in this study will be 35.
- Trial name
- NCT02913157
- Testing
- Hydroxychloroquine
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- University of Calgary
Bladder Dysfunction on Patients With Multiple Sclerosis
Effect of Behavioral Therapy Versus Interferential Current on Bladder Dysfunction in Patients With Multiple Sclerosis
study the effect of behavioral therapy and interferential current on management of bladder dysfunction in patients with multiple sclerosis
- Trial name
- MS (NCT04635709)
- Testing
- biofeedback training and interferential therapy
- Where
- Saudi Arabia
- Volunteers
- 50 people
- Sponsor
- Taibah University
Multiple Sclerosis, Trunk
Trunk Rehabilitation Compared to Core Stability in Patients With Multiple Sclerosis
BACKGROUND Balance, gait, community mobility, and risk of falls are often associated with trunk impairment among people with Multiple Sclerosis (PwMS).
- Conditions
- Multiple Sclerosis, Trunk, Physical Therapy
- Trial name
- NCT06447571
- Testing
- Trunk Rehabilitation, Core Stability
- Where
- Saudi Arabia
- Volunteers
- 40 people
- Sponsor
- King Abdulaziz University
Relapsing Multiple Sclerosis
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
A single arm study evaluating the continued efficacy, safety and tolerability of ofatumumab in patients with relapsing multiple sclerosis who are transitioning from aCD20 mAb therapy
- Trial name
- OLIKOS (NCT04486716)
- Testing
- Ofatumumab
- Where
- 20 sites in United States, Puerto Rico
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
potentiALS - Quality of Life Among Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and disabling disease with the majority of patients dying 3-5 years after symptom onset.
- Trial name
- potentiALS (NCT06441448)
- Testing
- case focus groups
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- University of Leipzig
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.